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therapy increased significantly for physicians in the inter-
vention group compared to physicians in the control
group during the post-intervention period (P  0.02).
This increase in eradication utilization was not accompa-
nied by a significant increase in the total cost of drug
therapy per patient for the intervention group compared
to the control group (P  0.82). The results from a 9-month
follow-up period will be presented. CONCLUSIONS:
The main goal of the study, to increase the utilization of
eradication therapy, was achieved in the 3-month follow-
up period. Observable modification of physician behav-
ior in only a three-month period is a positive finding, and
may indicate an even greater impact when the program is
evaluated over a longer period of time.
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OBJECTIVES: The optimal management strategy for pa-
tients with symptoms of GERD remains undefined. Our
objective was to examine the clinical and economic im-
pact of competing management strategies. METHODS:
Decision analysis was used to compare a traditional
“step-up” strategy with sequential invasive diagnostic
testing as needed to a strategy utilizing the initial “PPI
test” followed by a “step-down” approach with sequen-
tial diagnostic testing as needed. The cost per symptom-
free patient was assessed at 1-year. Systematic literature
review, Medicare payments and drug AWPs were used to
derive probability and cost estimates for the model.
Where there was uncertainty in the literature, estimates
were chosen to bias the model in favor of the traditional
management strategy. RESULTS: The average cost per
patient was $1045 and $1172 for the traditional “step-
up” and PPI test strategies, respectively. The percentage
of patients symptom-free at 1 year was 50% and 75%
for the traditional and PPI test strategies, respectively.
The incremental cost-effectiveness ratio for the PPI test
strategy was $510 per additional symptomatic cure. The
traditional strategy resulted in a greater than 5-fold in-
crease in endoscopy utilization but a 47% reduction in
ambulatory pH monitoring use. The reduced effective-
ness of the traditional strategy may be attributed to a
118% increase in the use of high-dose H2RAs while re-
ducing the use of PPIs by 42%–57%. The PPI test strat-
egy remained most cost-effective as long as the sensitivity
of the PPI test was greater than 23% and more than 47%
of patients with a positive PPI test received a “step-
down” trial. CONCLUSIONS: Strategies utilizing the
initial PPI test followed by a “step-down” approach may
result in improved symptom relief over 1 year, and more
appropriate utilization of invasive diagnostic testing at a
small marginal cost increase. These findings warrant a
prospective trial comparing these strategies.
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Recent work has shown that screening for Hepatitis C is
cost-effective from a societal perspective. Safety-net hos-
pitals are committed to providing care for their many un-
insured and underinsured patients who are unable to
pay. Adopting a screening policy would commit the insti-
tution to pay for expensive treatment for many of the
screened positives. OBJECTIVE: Examine the economic
implications for a safety-net hospital that adopts a Hepa-
titis C screening policy. METHODS: A Markov decision
analytic model was constructed, using a reference case of
a 35 year-old male without symptoms of Hepatitis C. The
perspective adopted was a safety-net hospital. Two popu-
lations were examined: uninsured, and insured, but with-
out coverage for combination interferonribavirin. Screen-
ing consisted of ELISA followed by a confirmatory PCR.
It was assumed that PCR and virus genotyping were sent
to an outside laboratory. Data came from prior publica-
tions. Patients were considered to be patients of this facility
for 5 years. RESULTS: In the uninsured group, screening
costs an additional $245 per patient, with an incremental
cost-effectiveness ratio (ICER) of $12,300/QALY. As
prevalence of infection ranged from 0.8%–9%, the addi-
tional cost of screening ranged from $77–$587, and the
ICER from $11,500/QALY–$16,800/QALY. In the under-
insured group, screening was associated with an addi-
tional cost of $166 per patient, with an ICER of $8300/
QALY. Varying the prevalence produced additional costs
of $38–$427. CONCLUSIONS: Although ICERs would
appear to be cost-effective from a societal perspective,
this is less clear for hospitals that deal with hard budgets,
not the soft budget, cost-conscious environment assumed
by incremental cost-effectiveness analysis. Screening for
Hepatitis C may be an expensive policy to implement for
safety-net hospitals. Public funding to support a screen-
ing and treatment program may be well justified.
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Recently reported data show that expenditures for pre-
scription drugs are rising more rapidly than spending for
other healthcare services. A number of studies have at-
tempted to decompose changes in prescription drug ex-
penditures but have been limited by types of data used,
pricing metrics, or failure to disaggregate growth into
factors related to particular therapies. OBJECTIVE: To
quantify the contribution of several volume and price fac-
tors to prescription drug expenditure growth for seven
drug/disease categories, and to measure the impact of
new entrants to the market on these factors. METHODS:
Using medical and drug claims data from two different
sources (1994–1997 and 1995–1998), total expenditure
growth for each category was disaggregated into three
price-related multiplicative factors (inflation, therapeutic
mix, new entrant drug prices) and five volume-related
multiplicative factors (prevalence, prescriptions per pa-
tient for new entrants and for established drugs, and days
per prescription for new entrants and for established
drugs). The drug categories selected for the analyses rep-
resent the highest spending or are among the fastest
growing categories reported in other studies. RESULTS:
We observed three-year increases in expenditures ranging
from 43–219% across the seven categories studied. The
percentage of growth attributed to all volume factors ver-
sus all price factors together ranged from 2.5:1 for hor-
mone replacement therapy to more than 10:1 for gas-
trointestinal agents and lipid-lowering drugs. These trends
may be associated with new scientific understanding and
better medical practice. CONCLUSION: As health plans
and payors assess the appropriateness of spending growth
within resource limits, disaggregation of expenditure
growth can identify significant components of growth
and help to determine the magnitude of the underlying
clinical and population drivers.
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OBJECTIVE: In Greece, a new pricing system and a pos-
itive list for pharmaceuticals were introduced in late
1997 to April 1998. This paper attempts to evaluate their
effectiveness on total and social insurance expenditures
after one implementation year. METHODS: In Decem-
ber 1997, pharmaceutical prices were re-calculated,
based on the lowest ex factory price for the same product
in EU. Levies on ex factory prices (earmarked social in-
surance (SI) taxes) were reduced. All drugs were classified
in categories of active substances. Those with individual
daily treatment cost higher than category averages were
excluded from the positive list. Using data from IMS and
the National Agency “Pharmetrica” we evaluate: total
expenditure growth after reforms, formulary exclusion
impact on products and therapeutic classes and trends in
SI expenditures and income. RESULTS: Price reform led
to average unit price reduction of 24%. Volume trends
remained initially stable increasing sharply in Q1/1999.
Positive list introduction lead to slight volume reduction
until 08/1999 followed by increasing value trends. The
list had no impact on average unit price. Total market ex-
penditures were reduced by 14% in 1998, albeit surpass-
ing 1997 levels in early 1999. Excluded products showed
sales decrease. Effects on therapeutic class value and vol-
ume growth varied. SI expenditures were reduced in the
short, but not in the long term. SI income lost from tax
reduction was replaced by government subsidies. CON-
CLUSION: Price control and drug list effects were short-
lived both on total and SI expenditures. Government fi-
nally had to subsidise price reduction for individual
products. Cost-effectiveness criteria and prescribing habit
controls may be more effective in future policy initiatives.
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Over the past decade there has been an enormous expan-
sion in outcomes research directed at influencing pre-
scribing and coverage decisions. However, little is known
about what types of information are best understood by
decision-makers and what information they would like to
have presented to them. OBJECTIVES: The purpose of
this study was to ascertain (1) the skills of managed care
decision-makers and the information that they prefer to
see presented to them (2) awareness of guidelines (3) im-
portance of indirect and caregiver costs, and (4) the per-
centage of products that have undergone a formal phar-
macoeconomic or quality of life review in the previous
year. METHODS: A telephone survey of 41 randomly se-
lected pharmacy and medical directors was conducted to
elicit their attitudes towards PE information. RESULTS:
In terms of rank order the following study designs were
preferred by respondents: RCTs, trials in HMO settings,
cost of treatment studies, models, observational studies
and retrospective chart analyses. The majority of respon-
dents reported that their P&T committees had at least a
good understanding of pharmacoeconomic (63.4%) and
QoL (58.5%) data. In 1998, 43.9% of products received
some form of pharmacoeconomic or QoL review prior to
formulary acceptance; however only four respondents
were aware of guidelines for the conduct and presenta-
tion of pharmacoeconomic studies. 36.6% and 38.8% of
respondents were neutral or not concerned with the indi-
rect cost of disease or caregiver burden, respectively.
CONCLUSIONS: The use of pharmacoeconomic infor-
mation in MCOs is beginning to show some promise.
MCOs feel that pharmacoeconomic and QoL data will
